Evidence map›Paper›PMID 34257586›Full record

ArticlePathology oncology research : POR2021

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.

Györgyi A Nelhűbel, Mihály Cserepes, Balázs Szabó, Dóra Türk, Adél Kárpáti, István Kenessey, Erzsébet Rásó, Tamás Barbai, Zita Hegedűs, Viktória László and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Györgyi A NelhűbelDepartment of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.
Mihály CserepesDepartment of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.
Balázs SzabóDepartment of Otolaryngology and Head and Neck Surgery, Semmelweis University, Budapest, Hungary.
Dóra TürkDepartment of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.
Adél KárpátiDepartment of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.
István Kenessey2 Institute of Pathology, Semmelweis University, Budapest, Hungary.
Erzsébet Rásó2 Institute of Pathology, Semmelweis University, Budapest, Hungary.
Tamás Barbai2 Institute of Pathology, Semmelweis University, Budapest, Hungary.
Zita HegedűsDepartment of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.
Viktória LászlóDepartment of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
Bálint SzokolVichem Chemie Ltd., Budapest, Hungary.
Judit DobosVichem Chemie Ltd., Budapest, Hungary.
László ŐrfiVichem Chemie Ltd., Budapest, Hungary.
József TóváriDepartment of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.
National Institute of Oncology · HUSemmelweis University · HUVichem Chemie (Hungary) · HUMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell ProliferationCetuximabErbB ReceptorsErlotinib HydrochlorideFemaleGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansIndolesMiceMice, SCIDPiperazines((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)CetuximabEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideIndolesMET protein, humanPiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins c-metSulfonamidesZoledronic Acidc-MetEGFRHNSCCR521Ktargeted tumor therapy

Identifiers

PMID34257586
PMCPMC8262169
OpenAlexW3158267661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.